The Comparison of Single-Dose and Extended-Dose Antimicrobial Prophylaxis for Preventing Surgical Site Infections After Curative Surgery for Gastric Adenocarcinoma
Single-Dose and Extended-Dose Antimicrobial Prophylaxis in Gastic Cancer Surgery
DOI:
https://doi.org/10.22317/jcms.v6i3.750Keywords:
Antibiotic Prophylaxis, Stomach Neoplasms, Surgical Wound InfectionAbstract
Objectives: There is no consensus on the duration of antimicrobial prophylaxis (AMP) for prevention of surgical site infections (SSI) after curative gastrectomy for gastric adenocarcinoma and the data is limited. In this study, we aimed to compare the effect of single-dose and extended-dose AMP on SSI prevention.
Methods: A total of 210 patients who underwent curative gastrectomy for gastric cancer included in the study. Patients who received a single dose of 1 g cefazolin 30 minutes before the surgical incision were determined as single-dose group and the patients who received 1 g cefazolin one time 30 minutes before the surgical incision and every 12 hours until the first postoperative day were determined as extended-dose group. Demographic characteristics, postoperative outcomes and the types and incidence of SSI were compared in two groups and risk factors for SSI development were analyzed.
Results: There was no significant difference in the demographic characteristics and postoperative outcomes in both AMP groups in the general patient population and in the subgroups formed based on different clinicopathological and operative factors. There was no significant difference in the incidence of SSI between the two groups (23,4% and 26,7% p = 0,346). Age, diabetes mellitus, chronic obstructive pulmonary disease (COPD), operation time and operative approach were found to be independent risk factors for SSI development.
Conclusion: In patients undergoing curative gastrectomy for gastric adenocarcinoma, it has been found that the use of extended-dose AMP has no effect on reducing the incidence of SSI and single-dose AMP is sufficient and safe.
References
2. Burke JP. Infection control - a problem for patient safety. N Engl J Med 2003;348:651-656.
3. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-485.
4. Migita K, Takayama T, Matsumoto S, Wakatsuki K, Enomoto K, Tanaka T et al. Risk factors for surgical site infections after elective gastrectomy. J Gastrointest Surg 2012;16: 1107-1115.
5. Ozalp N, Zülfikaroğlu B, Göçmen E, Acar A, Ekiz I, Koç M et al. Risk factors for surgical site infection after gastrectomy with D2 lymphadenectomy. Surg Today 2009; 39:1013-1015.
6. Gilbert DN, Moellering RC, Sande MA.. The Sanford Guide to Antimicrobial Therapy. 33rd ed. Hyde Park, VT: Antimicrobial Therapy, 2003:123-124.
7. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1999;20:250-278.
8. Bratzler DW, Houck PM, Richards C, Steele L, Dellinger EP, Fry DE et al. Use of antimicrobial prophylaxis for major surgery: baseline results from the National Surgical Infection Prevention Project. Archives of Surgery, 2005;140(2), 174-182.
9. Kobayashi M, Takesue Y, Kitagawa Y, Kusunoki M, Sumiyama Y. Antimicrobial prophylaxis and colon preparation for colorectal surgery: results of a questionnaire survey of 721 certified institutions in Japan. Surgery today, 2011; 41(10), 1363.
10. Mohri Y, Tonouchi H, Kobayashi M, Nakai K, Kusunoki M. Mie Surgical Infection Research Group. Randomized clinical trial of single- versus multiple-dose antimicrobial prophylaxis in gastric cancer surgery. Br J Surg 2007; 94:683-688.
11. Sumiyama Y, Takesue Y. Current status of prophylactic antibiotic therapy for prevention of postoperative infections after gastrointestinal surgery: a questionnaire covering 3,823 surgeons. Jpn J Chemother 2004; 52:474-485.
12. Sobin L, Gospodarowicz M, Wittekind C.. TNM classification of Malignant Tumours. 7th ed. International Union Against Cancer (UICC). New York: Wiley, 2009.
13. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann of Surg 2004; 240:205–213.
14. Ahn HS, Yook JH, Park CH, Park YK, Yu W, Lee MS et al. General perioperative management of gastric cancer patients at high-volume centers. Gastric Cancer 2011; 14:178-182.
15. Dellinger EP, Gross PA, Barrett TL, Krause PJ, Martone WJ, McGowan JE Jr et al. Quality standard for antimicrobial prophylaxis in surgical procedures. Infectious Diseases Society of America. Clin Infect Dis 1994;18:422-427.
16. Takayama T, Aramaki O, Shibata T, Oka M, Itamoto T, Shimada M et al. Antimicrobial prophylaxis for 1 day versus 3 days in liver cancer surgery: a randomized controlled non-inferiority trial. Surgery today 2019; 49(10), 859-869.
17. Hentzen JEKR, Smit MA, Bruins MJ, Rupert CGBM, Schreinemakers J, Ruijs GJHM et al. Efficacy of Pre-Operative Antimicrobial Prophylaxis in Patients Undergoing Pancreatoduodenectomy: A Multi-Center Retrospective Analysis. Surg Infect (Larchmt). 2018 Aug/Sep;19(6):608-613.
18. Ohashi M, Saka M, Katayama H, Okinaka K, Morita S, Fukagawa T et al. A Prospective Cohort Study To Evaluate the Feasibility of Intraoperative Antimicrobial Prophylaxis in Open Gastrectomy for Gastric Cancer. Surgical infections, 2015; 16(6), 833-839.
19. Imamura H, Furukawa H, Iijima S, Sugihara S, Tsujinaka T, Tsukuma H,et al. Multicenter phase II study of antimicrobial prophylaxis in low-risk patients undergoing distal gastrectomy for gastric cancer. Gastric Cancer 2006; 9: 32-35.
20. Imamura H, Kurokawa Y, Tsujinaka T, Inoue K, Kimura Y, Iijima S et al. Intraoperative versus extended antimicrobial prophylaxis after gastric cancer surgery: a phase 3, open-label, randomised controlled, non-inferiority trial. Lancet Infect Dis 2012; 12: 381-387.
21. Hirao M, Tsujinaka T, Imamura H, Kurokawa Y, Inoue K, Kimura Y et al; Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG). Overweight is a risk factor for surgical site infection following distal gastrectomy for gastric cancer. Gastric Cancer 2013;16: 239-244.
22. Utsumi M, Shimizu J, Miyamoto A, Umeshita K, Kobayashi T, Monden M et al. Age as an independent risk factor for surgical site infections in a large gastrointestinal surgery cohort in Japan. J Hosp Infect 2010; 75: 183-187.
